Theratechnologies (TSX:TH) EV-to-EBIT : 10.07 (As of Dec. 13, 2024)

View and export this data going back to 1998. Start your Free Trial

What is Theratechnologies EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Theratechnologies's Enterprise Value is C$120.2 Mil. Theratechnologies's EBIT for the trailing twelve months (TTM) ended in Aug. 2024 was C$11.9 Mil. Therefore, Theratechnologies's EV-to-EBIT for today is 10.07.

The historical rank and industry rank for Theratechnologies's EV-to-EBIT or its related term are showing as below:

TSX:TH' s EV-to-EBIT Range Over the Past 10 Years
Min: -302.28 Med: -11.65 Max: 720.18
Current: 10.07

During the past 13 years, the highest EV-to-EBIT of Theratechnologies was 720.18. The lowest was -302.28. And the median was -11.65.

TSX:TH's EV-to-EBIT is ranked worse than
50.24% of 420 companies
in the Biotechnology industry
Industry Median: 10.01 vs TSX:TH: 10.07

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Theratechnologies's Enterprise Value for the quarter that ended in Aug. 2024 was C$105.5 Mil. Theratechnologies's EBIT for the trailing twelve months (TTM) ended in Aug. 2024 was C$11.9 Mil. Theratechnologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Aug. 2024 was 11.32%.

Theratechnologies EV-to-EBIT Historical Data

The historical data trend for Theratechnologies's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theratechnologies EV-to-EBIT Chart

Theratechnologies Annual Data

Trend

Nov14

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Nov23

EV-to-EBIT

Get a 7-Day Free Trial

-32.79

-12.22

-12.89

-6.07

-6.88

Theratechnologies Quarterly Data
	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24
EV-to-EBIT	Get a 7-Day Free Trial															-3.06	-6.88	-12.96	18.67	8.83

Competitive Comparison of Theratechnologies's EV-to-EBIT

For the Biotechnology subindustry, Theratechnologies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Theratechnologies's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theratechnologies's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Theratechnologies's EV-to-EBIT falls into.

Theratechnologies EV-to-EBIT Calculation

Theratechnologies's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	120.190	/	11.939
	=	10.07

Theratechnologies's current Enterprise Value is C$120.2 Mil.
Theratechnologies's EBIT for the trailing twelve months (TTM) ended in Aug. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$11.9 Mil.

Theratechnologies (TSX:TH) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Theratechnologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Aug. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Aug. 2024 )	=	EBIT	/	Enterprise Value (Q: Aug. 2024 )
	=	11.939	/	105.4554
	=	11.32 %

Theratechnologies's Enterprise Value for the quarter that ended in Aug. 2024 was C$105.5 Mil.
Theratechnologies's EBIT for the trailing twelve months (TTM) ended in Aug. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$11.9 Mil.

Theratechnologies EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Theratechnologies's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Theratechnologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theratechnologies Inc (TSX:TH) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

THTX:USA TQ80:Germany TQ80:Germany

Address

2015, rue Peel, 11th Floor, Montreal, QC, CAN, H3A 1T8

Website

https://www.theratech.com

Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.

Executives

Dale Weil	Director
Joseph Arena	Director
Philippe Dubuc	Senior Officer
Gérald A. Lacoste	Director
Paul Lévesque	Senior Officer
Andrew Molson	Director
Dawn Svoronos	Director
John Leasure	Senior Officer
Alain Trudeau	Director
Sheila Frame	Director
Gary Peter Littlejohn	Director
Marie-noël Colussi	Senior Officer
Jovan Antunovic	Senior Officer
Christian Marsolais	Senior Officer
Jocelyn Lafond	Senior Officer